XERS
Xeris Biopharma Holdings, Inc.
NASDAQ · Healthcare
| Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|
| Revenue | ||||||
| Revenue | 291.8M | 203.1M | 163.9M | 110.2M | 49.6M | 20.2M |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Operating Expenses | ||||||
| R&D Expenses | — | — | — | — | — | — |
| SG&A Expense | — | — | — | — | — | — |
| Total Op. Expenses | — | — | — | — | — | — |
| Operating Income | 24.9M | -33.6M | -44.0M | -81.9M | -115.2M | -83.5M |
| EBITDA | — | — | — | — | — | — |
| Below the Line | ||||||
| Interest Expense | — | — | — | — | — | — |
| Pre-Tax Income | — | — | — | — | — | — |
| Income Tax | — | — | — | — | — | — |
| Net Income | 554,000 | -54.8M | -62.3M | -94.7M | -122.7M | -91.1M |
| Per Share | ||||||
| EPS (basic) | — | — | — | — | — | — |
| EPS (diluted) | — | — | — | — | — | — |
| Shares | ||||||
| Basic Shares | — | — | — | — | — | — |
| Diluted Shares | 173M | 147M | 138M | 136M | 79M | 60M |